VANCOUVER, BRITISH COLUMBIA--(CCNMatthews - June 2, 2006) - Allon Therapeutics Inc. (TSX:NPC), The Neuro Protection CompanyTM, today announced that patient enrolment has begun for a Phase II human clinical trial evaluating the Company’s product AL-208 as a treatment for the mild cognitive impairment (MCI) that commonly occurs following coronary artery bypass graft (CABG) surgery. Gordon McCauley, President and CEO of Allon, said the Phase II trial will evaluate the safety and effectiveness of AL-208 at preventing or reducing MCI in CABG surgery patients aged 65 to 79. Preventing or reducing MCI post-CABG has a potential market estimated at US$500-million for which there is no available treatment today.
